Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scheid

Showing results (1151-1160 of 1,291) with videos related to

Pageof 130
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Plant Physiology|November 6, 2016
Developmental Control and Plasticity of Fruit and Seed Dimorphism in Aethionema arabicumTeresa Lenser, Kai Graeber, Özge Selin Cevik, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Bone Marrow Transplantation|August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMTNoureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Bone Marrow Transplantation|April 23, 2022
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Katya Mauff, Dietrich Beelen, et al.
Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
JCI Insight|March 30, 2017
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birthDavid J Dowling, Simon D van Haren, Annette Scheid, et al.
Pageof 130

Showing results (1151-1160 of 1,291) with videos related to

Sort By:
Pageof 130
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Plant Physiology|November 6, 2016
Developmental Control and Plasticity of Fruit and Seed Dimorphism in Aethionema arabicumTeresa Lenser, Kai Graeber, Özge Selin Cevik, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Bone Marrow Transplantation|August 29, 2025
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMTNoureddine Henoun Loukili, Luuk Gras, Linda Koster, et al.
Nature Communications|November 18, 2023
TOF<sub>IMS</sub> mass spectrometry-based immunopeptidomics refines tumor antigen identificationNaomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Bone Marrow Transplantation|April 23, 2022
Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Katya Mauff, Dietrich Beelen, et al.
Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
JCI Insight|March 30, 2017
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birthDavid J Dowling, Simon D van Haren, Annette Scheid, et al.
Pageof 130